Bear- I’m assuming of course that the company would know whether or not the primary endpoint has been met at the time they decide to proceed with a US listing, and that everything else is already in place that would allow them to do that.  If topline is negative then market conditions would clearly not be favourable to pursuing a listing. Some assumptions and ‘if’s’ to be sure, but based on their initial intention perhaps still plausible.  We didn’t really expect the PO either but then here we are.  Management has had plenty of time to strategize the roll out of trial results so I’m just saying that this is a possibility.